Preclinical Autoimmunity Screening in High-Risk Individuals

Abstract

Preclinical autoimmunity screening in high-risk individuals is an evolving paradigm in preventive medicine, aiming to identify autoantibody-positive but asymptomatic persons before disease onset. This article reviews the epidemiology, pathophysiology, risk factors, clinical features, diagnostic strategies, and management options for preclinical autoimmune states, with a focus on common conditions such as type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus. We highlight recent advances, emerging therapies, and guideline-based recommendations for targeted screening, integrating mechanistic insights with clinical implications for early intervention and disease prevention.

Introduction

Autoimmune diseases represent a significant public health challenge, collectively affecting millions worldwide. The preclinical phase, characterized by the presence of autoantibodies or other immune perturbations in the absence of overt symptoms, provides a critical window for intervention. With advances in biomarker discovery and improved understanding of disease pathogenesis, early screening in individuals at high risk has gained interest for its potential to delay or prevent clinical onset. This review synthesizes current evidence and clinical guidelines to inform screening strategies in at-risk populations.

Epidemiology / Disease Burden

Autoimmune diseases such as type 1 diabetes (T1D), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE) are increasingly prevalent, with a combined global incidence estimated at over 5% of the population. Family members of affected individuals, especially first-degree relatives, face a substantially higher risk. For instance, siblings of T1D patients have a 15-fold increased risk compared to the general population. The morbidity and healthcare costs associated with late diagnosis drive interest in identifying individuals in preclinical stages who may benefit from surveillance or early intervention.

Pathophysiology

Preclinical autoimmunity is defined by the presence of pathogenic autoantibodies and/or autoreactive T cells before the emergence of clinical symptoms. In T1D, for example, seroconversion to islet autoantibody positivity often precedes hyperglycemia by months to years. The transition from tolerance to autoimmunity involves genetic susceptibility, environmental triggers, and dysregulated immune checkpoints. Molecular mimicry, epitope spreading, and loss of regulatory T cell function are key mechanisms underlying this progression. Understanding these mechanisms informs both the identification of high-risk individuals and the development of targeted preventive strategies.

Risk Factors

Risk factors for preclinical autoimmunity include genetic predisposition (e.g., HLA-DR/DQ haplotypes), positive family history, female sex (for most autoimmune diseases), and specific environmental exposures such as viral infections, smoking, and dietary factors. In RA, anti-citrullinated protein antibodies (ACPAs) often emerge years before symptom onset, particularly in those with a familial background or certain HLA-DRB1 alleles. For SLE, a constellation of genetic variants and environmental insults such as UV light exposure contribute to disease risk. Accurate risk stratification is essential to guide screening and monitoring protocols.

Clinical Features

By definition, preclinical autoimmunity is asymptomatic; however, subtle signs such as arthralgia, fatigue, or transient laboratory abnormalities may be present. Recent studies suggest that subclinical inflammation, detected by imaging or advanced biomarkers, can predate the first clinical event. The identification of specific autoantibody profiles such as GAD, IA-2, and ZnT8 in T1D, or ANA and anti-dsDNA in SLE helps to pinpoint individuals at highest risk for progression. Recognizing these features is crucial for physicians managing patients with a familial or personal history of autoimmunity.

Diagnosis

Diagnosis of preclinical autoimmunity relies on sensitive and specific serological assays. Multiplex platforms capable of detecting panels of autoantibodies (e.g., islet cell, ACPA, ANA) have improved screening accuracy. For T1D, the presence of two or more islet autoantibodies confers a nearly 100% lifetime risk for progression. In RA and SLE, high-titer autoantibodies and additional biomarkers such as interferon signatures or imaging findings (MRI, ultrasound) can support risk assessment. Screening protocols must balance the benefits of early detection with the psychological and ethical considerations of identifying at-risk but asymptomatic individuals.

Treatment & Management

Management in the preclinical phase is evolving. The primary approach involves close surveillance, patient education, and risk mitigation (e.g., smoking cessation, weight management). Clinical trials now explore the use of immunomodulatory agents such as teplizumab in T1D to delay or prevent disease onset. For RA, interventions targeting B cell activity or cytokine signaling are under investigation. Lifestyle modifications and avoidance of known environmental triggers are also recommended. Shared decision-making and psychological counseling play vital roles in supporting patients identified through screening.

Recent Advances / Emerging Therapies

Recent years have seen major advances in the field. The FDA approval of anti-CD3 monoclonal antibody teplizumab marked a milestone in T1D prevention, with studies demonstrating delayed onset in high-risk children. In RA, trials with tolerogenic dendritic cells and peptide-based immunotherapies are ongoing. Novel biomarkers including polygenic risk scores, metabolomics, and single-cell transcriptomics show promise for refining risk prediction. These advances may soon enable precision medicine approaches tailored to individual risk profiles and disease mechanisms.

Guideline Recommendations

International guidelines increasingly support targeted screening in high-risk groups. The American Diabetes Association recommends screening first-degree relatives of T1D patients for islet autoantibodies, particularly within research settings. The European League Against Rheumatism and the American College of Rheumatology support surveillance in individuals with familial RA, especially with positive ACPA. In SLE, current guidelines are more cautious, emphasizing research protocols due to lower predictive value of screening. All guidelines stress informed consent, counseling, and consideration of patient preferences.

Conclusion

Preclinical autoimmunity screening in high-risk individuals offers a promising frontier in preventive medicine. By identifying at-risk persons before symptom onset, clinicians may intervene to delay or avert disease, reduce complications, and improve long-term outcomes. As research uncovers new biomarkers and therapeutic targets, and as guidelines evolve, the integration of evidence-based screening into clinical practice will require careful balancing of benefits, risks, and ethical considerations. Ongoing collaboration between researchers, clinicians, and patients remains essential to maximize the potential of this preventive approach.